Free drug and ROS-responsive nanoparticle delivery of synergistic doxorubicin and olaparib combinations to triple negative breast cancer models

Cavanagh, Robert J.; Monteiro, Patrícia F.; Moloney, Cara; Travanut, Alessandra; Mehradnia, Fatemeh; Taresco, Vincenzo; Rahman, Ruman; Martin, Stewart G.; Grabowska, Anna M.; Ashford, Marianne B.; Alexander, Cameron

Abstract

Combinations of the topoisomerase II inhibitor doxorubicin and the poly (ADP-ribose) polymerase inhibitor olaparib offer potential drug-drug synergy for the treatment of triple negative breast cancers (TNBC). In this study we performed in vitro screening of combinations of these drugs, administered directly or encapsulated within polymer nanoparticles, in both 2D and in 3D spheroid models of breast cancer. A variety of assays were used to evaluate drug potency, and calculations of combination index (CI) values indicated that synergistic effects of drug combinations occurred in a molar-ratio dependent manner. It is suggested that the mechanisms of synergy were related to enhancement of DNA damage as shown by the level of double-strand DNA breaks, and mechanisms of antagonism associated with mitochondrial mediated cell survival, as indicated by reactive oxygen species (ROS) generation. Enhanced drug delivery and potency was observed with nanoparticle formulations, with a greater extent of doxorubicin localised to cell nuclei as evidenced by microscopy, and higher cytotoxicity at the same time points compared to free drugs. Together, the work presented identifies specific combinations of doxorubicin and olaparib which were most effective in a panel of TNBC cell lines, explores the mechanisms by which these combined agents might act, and shows that formulation of these drug combinations into polymeric nanoparticles at specific ratios conserves synergistic action and enhanced potency in vitro compared to the free drugs.

Citation

Cavanagh, R. J., Monteiro, P. F., Moloney, C., Travanut, A., Mehradnia, F., Taresco, V., Rahman, R., Martin, S. G., Grabowska, A. M., Ashford, M. B., & Alexander, C. (2024). Free drug and ROS-responsive nanoparticle delivery of synergistic doxorubicin and olaparib combinations to triple negative breast cancer models. Biomaterials Science, 12(7), 1822-1840. https://doi.org/10.1039/d3bm01931d

• Journal Article Type: Article
• Acceptance Date: Feb 14, 2024
• Online Publication Date: Feb 15, 2024
• Publication Date: Apr 7, 2024
• Deposit Date: Feb 15, 2024
• Publicly Available Date: Feb 15, 2024
• Journal: Biomaterials Science
• Electronic ISSN: 2047-4830
• Publisher: Royal Society of Chemistry
• Peer Reviewed: Peer Reviewed
• Volume: 12
• Issue: 7
• Pages: 1822-1840
• DOI: https://doi.org/10.1039/d3bm01931d
• Keywords: General Materials Science; Biomedical Engineering
• Public URL: https://nottingham-repository.worktribe.com/output/31448590
• Publisher URL: https://pubs.rsc.org/en/content/articlelanding/2023/bm/d3bm01931d